Recombinant human insulin is the world's first recombinant protein drug marketed for the treatment of type 1 and type 2 diabetes and has been used for more than 30 years. Development, insulin has now evolved from the first generation of animal-derived insulins to the fourth generation of long-acting insulin analogs. 

Recombinant human insulin is the world's first recombinant protein drug marketed for the treatment of type 1 and type 2 diabetes and has been used for more than 30 years. Development, insulin has now evolved from the first generation of animal-derived insulins to the fourth generation of long-acting insulin analogs. 

Recombinant protein drugs including:

1. Peptide hormones - recombinant human insulin, insulin analogs, recombinant human growth hormone and recombinant human follicle stimulating hormone, etc.

2. Cytokines -recombinant human follicle maturation hormone, recombinant human interferon  α、β、γ、 recombinant human granulocyte macrophage-stimulating factor, recombinant human erythropoietin, recombinant human interleukin 2,11, recombinant human epidermal growth factor. Recombinant human fibroblast growth factor, etc.

3. Recombinant enzymes - recombinant human urokinase progenitors, recombinant human α glucosidase preparations, etc., and others such as recombinant human bone formation Protein 2 and recombinant hirudin in various segments. 

The development of recombinant protein drugs is now in a stable phase and new technologies are important to extend the half-life of the drug in the body and change the form of delivery. Research into long-acting drugs is ongoing.